<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320407</url>
  </required_header>
  <id_info>
    <org_study_id>CAM5778</org_study_id>
    <nct_id>NCT04320407</nct_id>
  </id_info>
  <brief_title>Osia CPT Code Study</brief_title>
  <official_title>A Post-market Interventional Cohort Study Evaluating the Clinical Efficacy of the Osia 2 System in the US Market.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cochlear</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cochlear</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy of the Osia 2 system in patients with conductive or mixed
      conductive hearing loss in a US cohort.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adaptive speech in noise test for Osia 2 system.</measure>
    <time_frame>3 months</time_frame>
    <description>To demonstrate significant difference between the aided and unaided conditions in Osia 2 arm at 3 months using an adaptive speech in noise test when compared to the preoperative (Visit 1) unaided condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aided vs unaided differences between the Osia and Connect arms</measure>
    <time_frame>3 months; Connect cohort 1 study visit/end of study/3 months</time_frame>
    <description>To demonstrate a significant difference in the change from unaided to aided between the Osia and Connect arms using an adaptive speech in noise test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Conductive Hearing Loss</condition>
  <condition>Mixed Hearing Loss</condition>
  <arm_group>
    <arm_group_label>Osia 2 System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Osia 2 Active Osseointegrated Implant System for Bone Conduction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baha Connect System</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exisiting Baha Connect bone conduction device adults users</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Osia 2 System</intervention_name>
    <description>The external Sound Processor, Osia 2 Active Osseointegrated Implant System for Bone Conduction, captures and digitizes the sound which is transferred to the internal implant where it is converted to an electrical signal.
Reference device for Cohort 1 Osia: Baha 5 Power sound processor on the Baha Sound Arc.</description>
    <arm_group_label>Osia 2 System</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Baha Connect System</intervention_name>
    <description>Existing Baha Connect bone conduction device adult users matched audiometrically to Osia System cohort.</description>
    <arm_group_label>Baha Connect System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cohort 1 Osia:

               -  Willing and able to provide written informed consent.

               -  Proficient in English.

               -  Hearing loss etiology of Conductive or Mixed Conductive loss.

               -  Bone conduction PTA (.5, 1, 2, and 3 kHz) better than or equal to 55 dB HL in the
                  treatment ear.

               -  Aged 18 years and older.

        Cohort 2 Connect:

          -  Willing and able to provide written informed consent.

          -  Proficient in English.

          -  Hearing loss etiology of Conductive or Mixed Conductive loss.

          -  Bone conduction PTA (.5, 1, 2, and 3 kHz) better than or equal to 55 dB HL in the
             treatment ear

          -  Aged 18 years and older.

          -  Minimum 3 months duration of use with an appropriately fitted Baha Connect bone
             conduction device.

        Exclusion Criteria:

          -  Cohort 1 Osia:

               -  Unwilling to wear the treatment device or comply with the surgical and
                  rehabilitation requirements of the study.

               -  Unable or unwilling to comply with the requirements of the clinical investigation
                  as determined by the Investigator.

               -  Medical, audiological or psychological conditions, as judged by the investigator
                  that might contraindicate participation in the clinical investigation.

               -  Investigator site personnel directly affiliated with this study and/or their
                  immediate families; immediate family is defined as a spouse, parent, child, or
                  sibling.

               -  Cochlear employees or contractors engaged by Cochlear for the purposes of this
                  investigation.

               -  Currently participating, or participated within the last 30 days, in another
                  interventional clinical investigation/trial involving an investigational drug or
                  device.

               -  Prior experience with a surgical bone conduction treatment option

               -  Insufficient bone quality to support the BI300 implant as determined by the
                  surgeon

        Cohort 2 Connect:

          -  Unwilling to wear the treatment device or comply with the surgical and rehabilitation
             requirements of the study.

          -  Unable or unwilling to comply with the requirements of the clinical investigation as
             determined by the Investigator.

          -  Medical, audiological or psychological conditions, as judged by the investigator that
             might contraindicate participation in the clinical investigation.

          -  Investigator site personnel directly affiliated with this study and/or their immediate
             families; immediate family is defined as a spouse, parent, child, or sibling.

          -  Cochlear employees or contractors engaged by Cochlear for the purposes of this
             investigation.

          -  Currently participating, or participated within the last 30 days, in another
             interventional clinical investigation/trial involving an investigational drug or
             device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Syms, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arizona Hearing Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Cire</last_name>
    <phone>303 885 5440</phone>
    <email>gcire@cochlear.com</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>conductive hearing loss</keyword>
  <keyword>mixed hearing loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Conductive</mesh_term>
    <mesh_term>Hearing Loss, Mixed Conductive-Sensorineural</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Cochlear do not have an approved platform for public sharing of IPD collected in this study. Data may be provided to individual researchers on request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

